

A fully Bayesian parametric approach for cytogenetic dosimetry

Carlos Daniel Paulino^a, Giovani L. Silva^a and Márcia Branco^b

^a*Universidade Técnica de Lisboa and CEAUL*

^b*Universidade de São Paulo*

Abstract. This paper describes a new statistical analysis strategy to problems of cytogenetic dosimetry involving ordinal polythomous responses. Models relating the multivariate response to dose take the data ordinality into account and are analysed in a fully Bayesian fashion in the application here considered. In particular, these models are compared in order to select the best one for purposes of drawing inferences of interest and dose prediction is naturally addressed by its practical importance. This work was motivated by an in vitro experimental study on radiation exposure of human blood cell cultures, previously analysed in the literature by other methods, but its interest holds in many other applications of the biological and environmental field involving data sets yielded from the same type of assays for genetic damage.

1 Introduction

Cytogenetic dosimetry is a field of the dose-response studies dealing with the relationship between the level of exposure to radiation and some measure of genetic aberration, wherein a special interest is devoted to the calibration problem towards drawing inferences on unknown exposure doses for given observed responses. Bender et al. (1988) provide a comprehensive discussion of this topic and a general review of the statistical calibration problem can be found in Osborn (1991).

In this paper we confine ourselves to in vitro studies in which human blood samples are exposed to a range of doses of a given agent, and a polytomous response related to genetic aberrations is recorded for each dose. Specifically, we take the experimental study of radiosensitivity described in Ochi-Lohnmann et al. (1996) and Madruga et al. (1996) as an illustration of alternative procedures we propose in order to analyse data sets involving ordinal categorical responses in the framework of cytogenetic dosimetry problems. These problems are relevant in applications, namely, related to ecotoxicological studies and biomonitoring of human populations such as referred to in Fenech (2000).

Key words and phrases. Calibration, categorical data, continuation-ratio logits, Bayesian methods, nonlinear structural model..

Received November 2010; accepted April 2011.

Such experimental study involved lymphocytes cultures obtained from a few individuals belonging to three groups to be compared in terms of chromosomal susceptibility to ionizing radiation. One of them consisted of untreated cancer patients with basocellular carcinoma and the remaining ones are two control groups consisting of healthy subjects differing from each other in terms of age. The carcinoma group was made up of three patients (ages 47, 67 and 68 years old). The first control group consisted of four healthy young individuals (ages between 20 to 30 years old), and the second control group of two healthy old individuals (ages between 40 to 50 years old). Blood samples of each individual were divided into 8 lots and irradiated in a ^{60}Co source with doses of 0, 20, 50, 100, 200, 300, 400 and 500 cGy (at an average dose rate of 1 Gy/min).

Some of these samples were previously subject to a cytokinesis-block micronucleus assay with cytochalasin-B originating cells that completed only one nuclear division (binucleated cells). The data here considered refer to frequencies of cells displaying zero, one and two or more micronuclei out of the total of cells for every individual exposed to each radiation dose. These micronuclei, resulting from chromosome break or loss or whole chromosome that fail to incorporate the main nuclei during the mitosis process, express the DNA damage induced spontaneously or by radiation. Since genetic alterations are associated with the development of cancer, the quantification of lesions occurring in the cells such as these micronuclei may serve as an indicator of carcinogenic risk. For details on the cytokinesis-block micronucleus technique and its efficiency and sensitivity to detect DNA damage see, for example, Fenech (2000).

The same type of data was also obtained for (mononucleated) cells that did not undergo the aforementioned cellular division process in order to compare their susceptibility to radiation with that of binucleated cells. For convenience we reproduce the complete data set in Table 5 in the Appendix.

Madruga et al. (1996) based their analysis upon a Dirichlet posterior distribution for the original parameters of a multinomial model for the cell frequency vector that corresponds to a log-Dirichlet distribution of the second kind for the ordinary (baseline) logits. The latter is then approximated by a bivariate Normal distribution after Aitchison and Shen (1980). The nonlinear predictor relating these logits to dose levels they consider with no further comparative analysis is fitted by classical methods. Kottas et al. (2002), taking just a subset of the same data, use a linear relationship between the ordinary logits and log-dose and perform a Bayesian analysis based on a noninformative prior for the parameters of this linear predictor. The ensuing results are compared with those associated with a fully nonparametric analysis on cumulative probabilities based on Dirichlet processes.

This paper aims at developing a fully Bayesian analysis of the whole data set, with no concession to a hybrid approach and without falling into the theoretical and computational complexities of a nonparametric approach. Calibration models on parametric functions that allow for the data ordinal nature are considered and compared towards selecting the best one for purposes of drawing inferences of

interest. Further analytic examination of selected models is taken in order to compare the three groups, what enables to get a more parsimonious overall model. The selected calibration model for each group is used to predict dose levels for given further observed frequencies.

The layout of the paper is as follows. Section 2 introduces the statistical modelling of this cytogenetic dosimetry problem. In Section 3 a Bayesian analysis of the illustrative data set is described, with presentation and discussion of the results obtained. Section 4 is devoted to a summary and further comments on the approach followed in this work.

2 Statistical modelling

Focusing on the data set previously described, for each radiation dose d_i , $i = 1, 2, \dots, k$ ($k = 8$), which n_i cells were exposed to, the observable response vector is denoted by $\mathbf{Y}_i = (Y_{i2}, Y_{i1}, Y_{i0})$, where Y_{i2} is the number of cells with two or more micronuclei, Y_{i1} is the number of cells with one micronucleus and Y_{i0} is the number of cells with no micronucleus. Denoting the probability associated to the j th category under the i th dose by θ_{ij} , for each dose we define the vector $\boldsymbol{\pi}_i = (\theta_{i2}, \theta_{i1}, \theta_{i0})$ satisfying $\sum_{j=0}^2 \theta_{ij} \equiv \mathbf{1}'\boldsymbol{\pi}_i = 1$. The probability model considered is a product-multinomial family, with probability function

$$f(y_1, y_2, \dots, y_k | \{n_i, \boldsymbol{\pi}_i\}) = \prod_{i=1}^k n_i! \prod_{j=0}^2 \frac{\theta_{ij}^{y_{ij}}}{y_{ij}!}, \quad (2.1)$$

where $\sum_{j=0}^2 y_{ij} = n_i$.

The i th trinomial probability function, taking response category ordering into account, can be factored into a product of two binomial distributions, the marginal distribution for Y_{i2} and the conditional distribution for Y_{i1} given $n_i - Y_{i2}$,

$$f(y_{i2}, y_{i1} | n_i, \boldsymbol{\pi}_i) = f(y_{i2} | n_i, \theta_{i2}) f(y_{i1} | n_i - y_{i2}, \theta_{i1} / (\theta_{i1} + \theta_{i0})). \quad (2.2)$$

On reparametrizing these two binomial distributions to the corresponding ordinary logits, one obtains the so-called continuation-ratio logits

$$L_{i1} \equiv \ln\left(\frac{\theta_{i2}}{\theta_{i1} + \theta_{i0}}\right), \quad L_{i2} \equiv \ln\left(\frac{\theta_{i1}}{\theta_{i0}}\right), \quad (2.3)$$

that contrast each category with a grouping of categories from lower levels of the response ordinal scale. The formulae (2.1)–(2.3) extend to the case of more than 3 response categories (e.g., Agresti, 2002).

One may contemplate other link functions for the (theoretical) proportions of the two binomial components of the probability model. For instance, if an asymmetric link such as the complementary log-log (or extremity) function was to be considered, one would get transformations of the proportions of cells with fewer

than two micronuclei and the proportions of cells with none micronucleus within those with fewer than two micronuclei,

$$E_{i1} = \ln\{-\ln(\theta_{i1} + \theta_{i0})\}, \quad E_{i2} = \ln\left\{-\ln\left(\frac{\theta_{i0}}{\theta_{i1} + \theta_{i0}}\right)\right\}. \quad (2.4)$$

Dependence of π_i on the radiation dose is expressed through modelling the continuation-ratio logits (or the corresponding alternative link functions). The structural models here considered were chosen taking into account the empirical calibration curves and comparative purposes towards the selection of the “best” model in order to draw the inferences of interest. These models include a simple linear, quadratic and two nonlinear structures on $\{L_{ij} \equiv L_j(d_i, \delta_j)\}$, $j = 1, 2$; $i = 1, \dots, k$, where d_i denotes the i th dose and δ_j the parameter vectors of each structural model,

$$L_j(d_i, \delta_j) = \alpha_j + \beta_j d_i, \quad (2.5)$$

$$L_j(d_i, \delta_j) = \alpha_j + \beta_j d_i + \gamma_j d_i^2, \quad (2.6)$$

$$L_j(d_i, \delta_j) = \frac{\alpha_j}{\beta_j + d_i}, \quad (2.7)$$

$$L_j(d_i, \delta_j) = \gamma_j + \frac{\alpha_j}{\beta_j + d_i}. \quad (2.8)$$

The predictor functional structure of these models has often been used in the dose-response problem literature, even though applied to other probability models or parametric functions (see Madruga et al., 1994).

The statistical model for the observed data is expressed by

$$f(\{y_i\} | \{n_i, d_i\}, \{\delta_j\}) = \prod_{i=1}^k \left\{ \binom{n_i}{y_{i2}} \frac{e^{y_{i2} L_1(d_i; \delta_1)}}{(1 + e^{L_1(d_i; \delta_1)})^{n_i}} \right. \\ \left. \times \binom{n_i - y_{i2}}{y_{i1}} \frac{e^{y_{i1} L_2(d_i; \delta_2)}}{(1 + e^{L_2(d_i; \delta_2)})^{n_i - y_{i2}}} \right\}. \quad (2.9)$$

Due to absence of specific prior information on any model parameters, we adopted independent Normal distributions for each component of δ_j , $j = 1, 2$, centered on 0 and with a large variance (equal to 10^6). The analysis of this Bayesian model allows us to compare the diverse dose-response structures and draw parametric inferences of interest, as described in the following section.

When it is intended to predict an unknown dose which an individual with known response vector was exposed to, the sampling model (2.9) that was selected previously is augmented with the distributional factor corresponding to this further data. Denoting the additional response vector by $Y_0 = (Y_{0j}, j = 0, 1, 2)$, with

$\sum_{j=0}^2 Y_{0j} = n_0$, and its unknown dose by d_0 , the statistical model to be considered is

$$\begin{aligned} & f(\{y_i\}, y_0 | \{n_i, d_i\}, n_0, d_0, \{\delta_j\}) \\ &= \prod_{i=1}^k \{f(y_{i2} | n_i, d_i, \delta_1) f(y_{i1} | n_i - y_{i2}, d_i, \delta_2)\} \\ & \quad \times f(y_{02} | n_0, d_0; \delta_1) f(y_{01} | n_0 - y_{02}, d_0, \delta_2). \end{aligned} \quad (2.10)$$

The associated prior includes a further factor concerning the prior distribution assigned to the parameter of interest d_0 . Here we used a flat Normal distribution centered on the average of the observed doses. It must be truncated from negative values when deemed necessary.

3 Bayesian analysis of the data set

Based upon the statistical model described in Section 2, the analytical objectives include model selection for each group and cell type, parameter estimation for the chosen model for each setting group comparison under the same model and, above all, dose prediction for future individuals.

The complexity of the Bayesian models previously described demands resorting to Markov Chain Monte Carlo (MCMC) methods so as to obtain the posterior density for the respective parameters by simulation. For each model considered, the convergence and autocorrelation analysis by the usual methods (Gilks et al., 1996) of the simulated chain allowed us to retain a MCMC sample of size 10,000 by taking every 5th iteration of the sequence, after removing 5000 burn-in iterations. For reasons that have to do with the chain convergence, the analysis of the linear and quadratic models started with a previous standardization of the dose levels and with appropriate flat Normal priors centered on 0 for the associated parameters. The MCMC analysis was implemented in WinBugs (Lunn et al., 2000). Convergence diagnostics and determination of highest posterior density (HPD) credible intervals were carried out via BOA software (Smith, 2007).

Comparison of models was carried out by assessment of their goodness of fit and complexity through some measures as follows: deviance information criterion (DIC) (Spiegelhalter et al., 2002) and Carlin-Louis' version of Bayesian information criterion (BIC) (Carlin and Louis, 2000). The more refined approximation of BIC due to Raftery et al. (2007) was also considered, but its results (not shown) did not cause any change in the model ordering. Moreover, the posterior mean of the Pearson parametric function (PF) was obtained under appropriated transformation from the simulated values for δ_j , $j = 1, 2$. Notice that

Table 1 Comparison of continuation-ratio logit models based on posterior mean of Pearson function (PF), BIC_{CL} and DIC

Group	Model	Mononucleated cells			Binucleated cells		
		PF	BIC_{CL}	DIC	PF	BIC_{CL}	DIC
Basocellular carcinoma	Linear	386	554	511	184	344	311
	Quadratic	193	357	293	135	288	238
	Nonlinear I	195	<u>329</u>	286	114	<u>241</u>	207
	Nonlinear II	<u>183</u>	341	<u>275</u>	<u>99</u>	244	<u>192</u>
Healthy young	Linear	1101	1396	1352	284	463	428
	Quadratic	264	481	414	135	298	245
	Nonlinear I	250	429	384	<u>82</u>	<u>221</u>	<u>186</u>
	Nonlinear II	<u>85</u>	<u>264</u>	<u>196</u>	83	242	188
Healthy older	Linear	314	452	411	131	264	232
	Quadratic	<u>61</u>	<u>233</u>	<u>171</u>	37	185	137
	Nonlinear I	111	258	217	25	<u>154</u>	122
	Nonlinear II	72	242	178	<u>16</u>	162	<u>113</u>

$PF = \sum_{i=1}^8 \sum_{j=0}^2 \frac{(y_{ij} - n_i \theta_{ij})^2}{n_i \theta_{ij}}$, where the elements of π_i are written as function of δ_j 's according to formula (2.9).

Table 1 displays the results obtained for the logistic models (2.5)–(2.8). The model which fits “best,” as defined by each measure, is underlined in Table 1. The emphasis here placed on logit-based models is due to the fact that they showed a better behaviour than the corresponding models based upon the complementary log-log function (the respective results are omitted for the sake of space).

According to the criteria used, the best model depends on the group of subjects and type of cells. The nonlinear II model (2.8) may be taken as our choice for the carcinoma group, regardless of the cell type, as well as for mononucleated cells of the young healthy group and binucleated cells of the older healthy group. Note that in some cases BIC tends to penalize it more than DIC does in favour of the simpler nonlinear model. For binucleated cells of the young healthy group the nonlinear II model appears to be a little worse than its simpler counterpart, whereas the quadratic model presents the best performance for mononucleated cells related to the older healthy group.

Figure 1 portrays calibration curves for the three groups, drawn from the posterior means of δ_j , $j = 1, 2$, parameters wherein the symbol \circ represents the values of the empirical continuation-ratio logits, for the binucleated cells (the others are not shown for reasons of space saving). They show the fitting superiority in general of the nonlinear models over the quadratic one. The exception occurs for mononucleated cells of the older healthy group (figures left out for the above reasons).

The dose-response curves computed from the posterior means of $\{\theta_{ij}\}$, denoted by $\{\tilde{\theta}_{ij}\}$, for the selected model for each group (according to the criteria pointed




Figure 1 Observed and fitted continuation-ratio logits, L_{i1} (left) and L_{i2} (right), of binucleated cells for basocellular carcinoma (top), young healthy (middle) and older healthy (bottom) subjects.

above) are displayed in Figure 2. As expected, the estimated proportions of damaged (unaffected) cells tend to increase (decrease) in general with the dose levels. A noticeable exception is the case of the older healthy group for mononucleated cells, as a consequence of using the quadratic model. From a given high dose level the decrease of $\{\bar{\theta}_{i0}\}$ is reversed, in correspondence with an opposite monotony behaviour of $\{\bar{\theta}_{i1}\}$, as well as of $\{\bar{\theta}_{i2}\}$, though this latter feature is not captured




Figure 2 Posterior expected proportions of mono- (left) and binucleated (right) cells with none (top), one (middle) and two or more (bottom) micronuclei adjusted for each group, according to selected model (NL II: carcinoma + YH-mono + OH-bi; NL I: YH-bi; Quad: OH-mono).

over the dosage range of Figure 2. This unsatisfactory behaviour disappears if for the case at issue we adopt the nonlinear II model (the second best one in the class considered), in that the curves will follow a predictable and very similar pattern to the other two groups (results not shown for the sake of space). This illustrates how a very good model in light of observed data may lead to unwise extrapolations.

The curves concerning binucleated cells already show noticeable differences among the three groups over the range of high doses. The most pronounced decrease (increase) of $\{\bar{\theta}_{i0}\}$ ($\{\bar{\theta}_{i2}\}$) belongs to healthy young subjects. As opposed to Madruga et al. (1996), the curves for both $\{\bar{\theta}_{i0}\}$ and $\{\bar{\theta}_{i2}\}$ concerning both groups of healthy subjects are distinct. The sharpest descent of $\{\bar{\theta}_{i0}\}$ belongs to the healthy young group, which displays a similar ascent for $\{\bar{\theta}_{i2}\}$ as that for the carcinoma patients up to the highest observed dose. From here this latter group shows a more marked increase in agreement with findings of other studies (see, e.g., Fenech, 2002) wherein the same type of micronucleus assays has shown that individuals who develop some types of cancer and their relatives exhibit elevated sensitivity to the DNA-damaging effects of ionising radiation.

Table 2 displays parameter estimates regarding the model chosen by the criteria of Table 1 for each group \times cell type setting. We may add that fitting the nonlinear II model for binucleated cells of the young healthy group, the 95% HPD credible intervals for the parameters γ_1 ($[-0.405, 1.052]$) and γ_2 ($[-0.275, 0.337]$) suggest that the nested model without these parameters can be a better alternative in accordance with the model comparison results in Table 1.

The nonlinear II model can still be reduced in light of the data by elimination of just one parameter γ_j for the group of carcinoma patients irrespective of the cell type ($\gamma_1 = 0$) and for binucleated cells of the older healthy subjects ($\gamma_2 = 0$). The evidence of γ_2 , actually related to an ordinary logit [recall (2.3)] being statistically significant for mononucleated cells of the carcinoma and young healthy subjects points out against the choice of the nonlinear I model by Madruga et al. (1996), reinforcing the comparative outcomes in Table 1.

Comparisons among the three groups can be made by integrating the corresponding product-trinomial distributions when parameterized by the same kind of structural model. For instance, for binucleated cells there is evidence that carcinoma and young healthy groups share the same parameters γ_1 and α_1 . An analogous conclusion regarding γ_2 , α_2 and β_2 holds within the two healthy groups. See Table 3.

Once we have selected a dose-response model in light of the experimental calibration data, we can use it towards estimation of unknown doses which blood cells of further individuals had been exposed to. With illustrative purposes we consider two new individuals by each group whose responses concerning binucleated cells are displayed in Table 4. The results were obtained by using the nonlinear model that was selected previously for each group.

The dose estimation is relatively precise a posteriori for the first three subjects whose data suggest their blood cells would have been exposed to moderate doses. There is evidence that the remaining ones would have had their cells submitted to higher doses, possibly beyond the larger dose used in the calibration experiment, what accounts for the fact that their HPD credible intervals tend to be substantially wider. This was obviously expected on the grounds that dose prediction for the latter cases correspond to an extrapolation. The higher are the doses implied by

Table 2 Posterior estimates for selected model parameters

Group	Parameter	Mononucleated cells			Binucleated cells		
		Mean	S.D.	95% HPD CI	Mean	S.D.	95% HPD CI
Basal cellular carcinoma	α_1	-3437	568.4	(-4554, -2358)	-2240	532.7	(-3315, -1276)
	α_2	-1081	143.6	(-1370, -819.4)	-285.8	67.44	(-421.7, -173.4)
	β_1	436.8	52.27	(333.2, 536.8)	365.9	66.77	(238.8, 498.2)
	β_2	218.7	23.86	(174.4, 266.9)	80.74	19.91	(45.68, 119.8)
	γ_1	0.281	0.438	(-0.537, 1.173)	0.636	0.447	(-0.212, 1.528)
	γ_2	-0.698	0.177	(-1.032, -0.347)	-0.600	0.135	(-0.849, -0.332)
Healthy young	α_1	-2066	368.6	(-2814, -1406)	-1220	45.02	(-1313, -1137)
	α_2	-501.9	33.17	(-567.8, -438.3)	-567.3	19.52	(-605.3, -529.2)
	β_1	290.6	41.54	(211.4, 371.9)	197.1	13.6	(170.5, 223.5)
	β_2	88.14	6.323	(76.01, 100.6)	133.7	7.261	(119.2, 147.6)
	γ_1	-0.862	0.357	(-1.532, -0.144)	-	-	-
	γ_2	-1.398	0.068	(-1.529, -1.263)	-	-	-
Healthy older	α_1	-7.036	0.144	(-7.326, -6.761)	-515.1	192.5	(-900.1, -229.6)
	α_2	-4.988	0.054	(-5.095, -4.884)	-587.9	149.2	(-885.5, -335.6)
	β_1	0.011	0.0012	(0.009, 0.014)	118.7	44.24	(48.31, 207.7)
	β_2	0.012	0.0005	(0.011, 0.013)	166.1	36.43	(102.7, 240.1)
	γ_1	-9×10^{-6}	2×10^{-6}	(-1×10^{-5} , -5×10^{-6})	-1.267	0.282	(-1.764, -0.698)
	γ_2	-1×10^{-5}	9×10^{-7}	(-2×10^{-5} , -1×10^{-5})	0.018	0.204	(-0.368, 0.420)

Table 3 Posterior interval estimates for comparison among group parameters for binucleated cells concerning nonlinear II model

Parameter	95% HPD CI	Parameter	95% HPD CI	Evidence
$\gamma_1^C - \gamma_1^{HY}$	(-0.476, 1.148)	$\gamma_2^C - \gamma_2^{HY}$	(-0.953, -0.299)	$\gamma_1^C = \gamma_1^{HY} \neq \gamma_1^{HO}$
$\gamma_1^C - \gamma_1^{HO}$	(0.998, 2.803)	$\gamma_2^C - \gamma_2^{HO}$	(-1.037, -0.204)	$\gamma_2^C \neq \gamma_2^{HY} = \gamma_2^{HO}$
$\gamma_1^{HY} - \gamma_1^{HO}$	(0.794, 2.333)	$\gamma_2^{HY} - \gamma_2^{HO}$	(-0.406, 0.412)	
$\alpha_1^C - \alpha_1^{HY}$	(-1662, 113.0)	$\alpha_2^C - \alpha_2^{HY}$	(117.9, 497.2)	$\alpha_1^C = \alpha_1^{HY} \neq \alpha_1^{HO}$
$\alpha_1^C - \alpha_1^{HO}$	(-2772, -790.6)	$\alpha_2^C - \alpha_2^{HO}$	(42.5, 595.8)	$\alpha_2^C \neq \alpha_2^{HY} = \alpha_2^{HO}$
$\alpha_1^{HY} - \alpha_1^{HO}$	(-1678, -346.3)	$\alpha_2^{HY} - \alpha_2^{HO}$	(-272.4, 291.1)	
$\beta_1^C - \beta_1^{HY}$	(19.20, 247.90)	$\beta_2^C - \beta_2^{HY}$	(-102.07, -11.00)	$\beta_1^C \neq \beta_1^{HY} \neq \beta_1^{HO}$
$\beta_1^C - \beta_1^{HO}$	(112.00, 383.61)	$\beta_2^C - \beta_2^{HO}$	(-157.90, -17.60)	$\beta_2^C \neq \beta_2^{HY} = \beta_2^{HO}$
$\beta_1^{HY} - \beta_1^{HO}$	(9.60, 221.56)	$\beta_2^{HY} - \beta_2^{HO}$	(-99.50, 35.00)	

Table 4 Dose posterior estimates for the calibration problem under the chosen nonlinear models for binucleated cells of two subjects per group

Observed responses	Posterior dose estimates		
	Mean	S.D.	95% HPD CI
$y_{0C}^{(1)} = (76, 240, 1186)$	232.8	17.58	(198.7, 267.5)
$y_{0HY}^{(1)} = (176, 401, 1930)$	252.2	10.95	(230.3, 273.2)
$y_{0HO}^{(1)} = (72, 241, 890)$	255.7	21.44	(214.3, 298.2)
$y_{0C}^{(2)} = (270, 451, 1083)$	606.6	47.8	(520.7, 701.8)
$y_{0HY}^{(2)} = (362, 725, 1329)$	582.8	26.43	(532.1, 635.3)
$y_{0HO}^{(2)} = (160, 319, 660)$	727.4	138.3	(515.0, 996.5)

the observed proportions, the larger is the predictive variability and wider are the credible intervals for the predicted dose. This is what one would obtain had we taken the more extreme cases exemplified in Madruga et al. (1996).

4 Concluding remarks

This paper offers a new modelling approach to problems of cytogenetic dosimetry involving ordinal polytomous responses based on an appealing factorization of the product-multinomial probability function into binomial factors related to appropriate ratios of category probabilities. This allows us to contemplate several types of models for functions of these conditional probabilities, such as logits, probits and extremits, that take the data ordinal nature into account. In the application here

revisited, involving the cytokinesis-block micronucleus assay, nonlinear parametric models in continuation-ratio logits have played an important role, namely, in assessing their fit and reduction and performing inverse prediction, in particular, outperforming the alternative use of cumulative logits.

Of course distinct models might be entertained. In a preliminary study, specification of a cubic spline structure with a knot succeeded for some settings in terms of aforementioned model comparison criteria. Specifically, these new models behaved better than the nonlinear parametric models for binucleated cells of carcinoma and young healthy groups. Also, other asymmetric functions of those conditional probabilities can still be addressed with the purposes of fit comparison and possible simplification of the predictor form.

The analysis of the model followed a fully Bayesian route based on usual non-informative priors for the model predictor parameters, on the grounds that prior information was unavailable. It enabled us to make additional inferences and get some distinguishing outcomes from those concerning a hybrid analysis of the illustrative data set previously performed by Madruga et al. (1996). We believe that in such dosimetry problems there may be experts with prior beliefs on the original category probabilities, which may be elicited and accommodated in some convenient prior distribution (e.g., Dirichlet). In such cases, it may be possible to convert this to the corresponding prior for the predictor parameters through the Bedrick et al. (1996) approach, following a procedure analogous to that used by Paulino et al. (2003) for binary data.

A more careful analysis of the data set suggests that the probabilistic model product-multinomial considered in (2.1), and also used by the previous authors (Madruga et al., 1996 and Kottas et al., 2002), may not be the best model for these data. Since several blood samples were taken from the same individual, the assumption of independence among the vectors of responses can be questionable. In this case, a random effect model could be considered with the goal to add a dependence structure between the responses. However, this would require unravelling the counts for each individual, but it was not possible to obtain this additional information.

The kind of analysis performed and the aforementioned suggestions are useful for many other applications of the cytokinesis-block micronucleus technique, yielding data of a similar nature, among which we emphasize radiation sensitivity testing both for cancer risk assessment and optimisation of radiotherapy, testing of new pharmaceuticals and agrichemicals, problems in ecotoxicology and nutrition and biomonitoring of human populations (see Fenech, 2000, and references therein).

Appendix: Data set table

Table 5 *Observed frequencies for mono and binucleated cells*

Dose	Mononucleated			Binucleated		
	y_{i0}	y_{i1}	y_{i2}	y_{i0}	y_{i1}	y_{i2}
Patients with basal cellular carcinoma						
0	20,442	68	6	1492	13	6
20	25,183	96	14	1478	45	4
50	27,614	362	81	1504	150	35
100	27,845	392	30	1305	125	13
200	13,378	527	72	1231	203	38
300	6359	398	74	1156	289	111
400	6234	531	148	1038	305	126
500	3920	449	180	1001	392	222
Healthy young subjects						
0	51,237	28	7	2341	31	1
20	23,891	81	28	2611	45	6
50	26,688	172	32	1849	117	25
100	25,916	465	56	1811	189	47
200	23,482	926	141	2204	325	82
300	8523	681	140	1734	501	207
400	9808	799	204	1621	523	254
500	7684	842	288	1005	456	285
Healthy older subjects						
0	15,551	114	12	920	31	2
20	13,953	96	20	989	41	8
50	16,163	180	18	933	56	14
100	13,319	291	38	939	114	32
200	6411	333	52	794	176	67
300	6699	366	75	683	209	59
400	4311	409	105	742	256	107
500	4689	370	152	771	327	143

Acknowledgments

This paper was partially supported by FCT-Portugal through the Center of Statistics and Applications (CEAUL). The authors thank Kayo Okazaki for her comments on biological issues related to this experimental study and one anonymous referee for his/her constructive suggestions and comments.

References

- Agresti, A. (2002). *Categorical Data Analysis*, 2nd ed. Hoboken, NJ: Wiley-Interscience. MR1914507

- Aitchison, J. and Shen, S. M. (1980). Logistic-normal distributions: Some properties and uses. *Biometrika* **67**, 261–272. [MR0581723](#)
- Bedrick, E. J., Christensen, R. and Johnson, W. (1996). A new perspective on priors for generalized linear models. *Journal of the American Statistical Association* **91**, 1450–1460. [MR1439085](#)
- Bender, M. A., Awa, A. A., Brooks, A. L., Evans, H. J., Groer, P. G., Littlefield, L. G., Pereira, C. A., Preston, F. J. and Wachholz, B. W. (1988). Current status of cytogenetic procedures to detect and quantify previous exposures to radiation. *Mutation Research* **196**, 103–159.
- Carlin, B. P. and Louis, T. A. (2000). *Bayes and Empirical Bayes Methods for Data Analysis*, 2nd ed. Boca Raton, FL: Chapman & Hall/CRC Press.
- Fenech, M. (2000). The in vitro micronucleus technique. *Mutation Research* **455**, 81–95.
- Fenech, M. (2002). Chromosomal biomarkers of genomic instability relevant to cancer. *Drug Discovery Today* **7**(22), 1128–1137.
- Gilks, W. R., Richardson, S. and Spiegelhalter, D. J. (1996). *Markov Chain Monte Carlo in Practice*. London: Chapman & Hall. [MR1397966](#)
- Kottas, A., Branco, M. D. and Gelfand, A. E. (2002). A nonparametric Bayesian modelling approach for cytogenetic dosimetry. *Biometrics* **58**, 593–600. [MR1925555](#)
- Lunn, D. J., Thomas, A., Best, N. G. and Spiegelhalter, D. J. (2000). WinBUGS—a Bayesian modelling framework: Concepts, structure, and extensibility. *Statistics and Computing* **10**, 325–337.
- Madrugá, M. R., Pereira, C. A. and Rabello-Gay, M. N. (1994). Bayesian dosimetry: Radiation dose versus frequencies of cells with aberrations. *Environmetrics* **5**, 47–56.
- Madrugá, M. R., Ochi-Lohmann, T. H., Okazaki, K., Pereira, C. A. and Rabello-Gay, M. N. (1996). Bayesian dosimetry II: Credibility intervals for radiation dose. *Environmetrics* **7**, 325–331.
- Ochi-Lohmann, T. H., Okazaki, K., Madrugá, M. R., Pereira, C. A. and Rabello-Gay, M. N. (1996). Radiosensitivity of blood lymphocytes from basocellular carcinoma patients, as detected by micronucleus assay. *Mutation Research* **357**, 97–106.
- Osborn, C. (1991). Statistical calibration: A review. *International Statistical Review* **59**, 309–336.
- Paulino, C. D., Soares, P. and Neuhaus, J. (2003). Binomial regression with misclassification. *Biometrics* **59**, 670–675. [MR2004272](#)
- Raftery, A., Newton, M., Satagopan, J. and Krivitsky, P. (2007). Estimating the integrated likelihood via posterior simulation using the harmonic mean identity (with discussion). In *Bayesian Statistics 8* (J. Bernardo et al., eds.) 371–416. Oxford: Oxford Univ. Press. [MR2433201](#)
- Smith, B. J. (2007). Bayesian Output Analysis Program (BOA), version 1.1.6. Univ. Iowa. Available from <http://www.public-health.uiowa.edu/boa>.
- Spiegelhalter, D. J., Best, N. G., Carlin, B. P. and Van der Linde, A. (2002). Bayesian measures of model complexity and fit (with discussion). *Journal of the Royal Statistical Society, Ser. B* **64**, 583–616. [MR1979380](#)

C. D. Paulino
 G. L. Silva
 Department of Mathematics
 Instituto Superior Técnico
 Universidade Técnica de Lisboa and CEAUL
 Lisbon
 Portugal
 E-mail: dpaulino@math.ist.utl.pt
gsilva@math.ist.utl.pt

M. Branco
 Department of Statistics
 Instituto de Matemática e Estatística
 Universidade de São Paulo
 São Paulo, SP
 Brazil
 E-mail: mbranco@ime.usp.br